Meeting
2023 ASCO Genitourinary Cancers Symposium
EDEN (Etude Désescalade sEmiNome): Prospective therapeutic de-escalation and miRNA-M371 biomarker evaluation phase II study for stage IIa/IIb < 3 cm seminomas.
Authors
Armelle Vinceneux
Departement of Medical Oncology, Centre Léon Bérard, Lyon, France
Armelle Vinceneux , David Pasquier , Ellen Blanc , Valéry Attignon , Pierre Blanchard , Aude Flechon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05529251
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS434)
DOI
10.1200/JCO.2023.41.6_suppl.TPS434
Abstract #
TPS434
Poster Bd #
N16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
Poster
2017 ASCO Annual Meeting
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation.
First Author: Ligang Xing